WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Alexion, AstraZeneca Rare Disease, will showcase 14 studies, including real-world evidence (RWE), from their portfolio and pipeline of ...
As CAR T-cell therapy has become a transformative option in multiple myeloma, a first-of-its-kind trial now extends that potential to relapsed/refractory light chain (AL) amyloidosis. At the recent ...
AstraZeneca’s plans to get an amyloidosis drug to market look further out of reach after the pharma’s anti-fibril antibody failed to reduce deaths and hospitalizations in a key phase 3 study. The Big ...
FDA Authorizes Device for Dialysis-Related Amyloidosis Patient and graft survival rates were 85.5% and 75.8%, respectively, at 5 years. New study findings support kidney transplantation to treat ...
In their study published in the Mayo Clinic Proceedings, UAB researchers collaborated with researchers from Weill Cornell Medicine and Columbia University to show that carpal tunnel syndrome preceded ...
Patients were classified by phenotype and genotype and assessed by a range of validated scales in common use internationally. The cardiac phenotype was the most predominant one globally, affecting ...
Please provide your email address to receive an email when new articles are posted on . An AI model accurately distinguished cardiac amyloidosis from other phenotypic mimics. The model also showed ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results